Impact of Reimbursement for Biomarker Testing on Clinical Practice

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”

Related Videos

December 18, 2018

Financial Constraints to Molecular Biomarker Testing

Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.

January 4, 2017

Serotonin and Carcinoid Tumors

Hal Gerstein, MD, details this neurotransmitter’s role in the development of carcinoid tumors and carcinoid syndrome.